Researchers trying to crack one of medicine's most perplexing unsolved mysteries can now keep abreast of late-breaking developments via the Schizophrenia Research Forum, a website launched this month ...

A public discussion on schizophrenia is taking place in Milton later this month. The Schizophrenia Society of Ontario is inviting Halton residents who are directly or indirectly affected by ...

New research shows that schizophrenia is not a single disease, but a group of eight distinct disorders, each caused by changes in clusters of genes that lead to different sets of symptoms. The finding ...

This story originally appeared on the Schizophrenia Research Forum. 30 April 2008. Does a seven-year-old mouse model that mirrors schizophrenia traits bring good luck? The mouse, missing BACE1 (β-site ...

WALTHAM, Mass.--(BUSINESS WIRE)--FORUM Pharmaceuticals Inc. today announced topline results from two Phase 3 clinical trials in patients with cognitive impairment in schizophrenia (CIS). While ...

About 200 people attended a mental health forum at the Franco-Manitoban Cultural Centre Wednesday night. "Facts and Myths about People Living with Schizophrenia and Psychosis" was organized by the ...

For Henry Cockburn, the onset of schizophrenia felt like pure common sense. It was February 2002, and the 20-year-old art student had strayed from the University of Brighton to satisfy his desire for ...

Li had spent seven years in the Selkirk Mental Health Centre before being moved to the Health Sciences Centre in February. He was approved to move to a group home earlier in May. The Manitoba ...

Forum Pharmaceuticals has gotten out from under an FDA clinical hold on a Phase III schizophrenia study for its lead drug, but the company's efforts to develop the treatment for Alzheimer's disease ...

WALTHAM, Mass.--(BUSINESS WIRE)--FORUM Pharmaceuticals Inc., a biopharmaceutical company singularly focused on the development and delivery of transformative medicines to treat serious brain diseases, ...

FORUM Pharmaceuticals announced topline results yesterday of its experimental drug encenicline, reporting that it missed primary endpoints in two Phase 3 trials of schizophrenia patients. The drug ...

Forum Pharmaceuticals announced that the Food and Drug Administration (FDA) has granted Fast Track designation to encenicline for the treatment of cognitive impairment in schizophrenia. Forum recently ...